SynsoryBio
Overview
SynsoryBio is a cutting-edge biotechnology company that focuses on developing next-generation protein therapeutics, particularly for cancer and autoimmune diseases. Founded in 2023 by Elliot and Nathan Tague, the company operates out of Cambridge, Massachusetts. SynsoryBio specializes in integrating "if-then" conditional logic into protein drugs, which allows these drugs to activate only at disease sites, thereby potentially increasing safety and effectiveness. To date, SynsoryBio has raised approximately $500,000, including investments from Y Combinator.
Recent Developments
- 2024: SynsoryBio completed a $500,000 Seed funding round, with Y Combinator as one of the key investors. This round is aimed at further developing its core technology and expanding its therapeutic solutions.
- 2023: SynsoryBio was included in the Innovate@BU Summer Accelerator program, which provides mentorship and resources aimed at early-stage companies. This opportunity helped SynsoryBio refine its business strategy and expand its technological reach.
- The company has consistently emphasized collaboration with immunologists and oncologists to enhance the application of its technology.
Company Information
| Attribute | Information |
|---|---|
| Founding Date | 2023 |
| Headquarters | Cambridge, MA |
| Founders | Elliot Tague, Nathan Tague |
| Revenue | Undisclosed |
| Profits | Undisclosed |
| Key Investors | Y Combinator |
| Industry | Biotechnology |
| Number of Employees | 2 |
Early History
SynsoryBio was founded by brothers Elliot and Nathan Tague, both of whom hold PhDs in biomedical engineering. The inspiration for the company arose from their work in synthetic biology and protein engineering, aiming to address the limitations of current systemic therapeutic delivery methods. By creating drugs that only activate in the presence of disease markers, they sought to tackle the safety concerns and dosage limitations associated with potent immunotherapies.
Company Profile and Achievements
SynsoryBio employs a platform that incorporates synthetic biology to design protein therapeutics with conditional activation capabilities. This "if-then" logic enables drugs to remain inactive until they detect specific disease markers, thus broadening their therapeutic window.
- 2013-2019: Founders gained experience at Boston University and Harvard, where they honed their expertise in synthetic biology. They contributed to numerous patents and scholarly articles, laying the groundwork for SynsoryBio's founding.
- 2023: The company was officially launched and attracted attention by participating in premium industry accelerators.
- 2024: Successfully secured seed funding to further its research and development initiatives.
Current Operations and Market Position
Today, SynsoryBio is at the forefront of therapeutic innovation, particularly in the field of oncology and chronic autoimmune conditions. The company leverages its proprietary platform to aim at highly toxic cancer immunotherapies, making them safer without losing efficacy. With the backing of Y Combinator, SynsoryBio is scaling its operations to bring these novel therapeutics to a wider market faster.
Conclusion
SynsoryBio stands as a promising newcomer in the biotechnology industry with a unique, innovative approach to combatting complex diseases through precision medicine. As it continues to grow and develop its technology, SynsoryBio has the potential to make significant impacts in therapeutic market landscapes like oncology and autoimmune disorders, presenting a future rich with possibilities for safer and more effective treatments.